DHT elevated — what it means alongside testosterone
Dihydrotestosterone (DHT) is the most potent endogenous androgen — 3-5× more potent than testosterone at the androgen receptor — and is produced peripherally from testosterone via 5α-reductase enzymes (types 1 and 2). DHT is responsible for prostate growth, scalp hair-follicle miniaturisation (male-pattern baldness), facial / body hair development, and adolescent male sexual differentiation. Elevated serum DHT can reflect: high circulating testosterone with proportional conversion, increased 5α-reductase activity (genetic or topical/oral exogenous androgen), or 5α-reductase inhibitor effects in reverse (washout). Reference ranges vary widely by lab and assay.
Reference ranges
| Standard reference — adult male | 30 – 85 ng/dL |
| Optimal (research) | 40 – 70 ng/dL |
| Elevated | > 85 ng/dL |
| DHT:testosterone ratio (research) | ~1:10 |
What this marker measures
Serum DHT measures circulating dihydrotestosterone, but most DHT acts intracellularly in target tissues (prostate, hair follicles) and isn't fully reflected in serum. Tissue-level androgen receptor activation depends on local 5α-reductase activity and androgen receptor density, neither captured by serum DHT. The serum value is mostly useful for tracking 5α-reductase inhibitor effects (finasteride, dutasteride) or confirming exogenous androgen exposure with high T-to-DHT conversion.
Why might it be elevated?
- ·High testosterone with proportional 5α-reductase conversion
- ·Anabolic steroid use (esp. DHT-class compounds)
- ·Topical / transdermal testosterone (high local skin DHT)
- ·Genetic 5α-reductase polymorphisms
- ·Adrenal androgen excess
Why might it be low?
- ·5α-reductase inhibitor use (finasteride, dutasteride)
- ·Genetic 5α-reductase deficiency (rare; ambiguous genitalia at birth)
- ·Low testosterone
FAQ
Should I take finasteride?+
Clinical decision — outside research-context framing here. Finasteride blocks 5α-reductase type 2 (~70% serum DHT reduction); dutasteride blocks types 1 and 2 (~95%). Used for male-pattern hair loss and benign prostatic hyperplasia. Side-effect profile (sexual dysfunction, mood) is non-trivial and post-finasteride syndrome is a recognised entity. Discuss with a clinician.
This page describes biomarker research and reference ranges for self-tracking and research-context discussion only. It is not medical advice, not a diagnosis, and not a substitute for a qualified physician. Take any concerns about your health to a clinician.
Have your own panel? Read it next to the standard reference ranges with our free analyse tool.
Analyse my blood work →- BiomarkerDHEA-S 80 µg/dL
Dehydroepiandrosterone sulphate at 80 µg/dL in a man in his 40s is below the typical age-matched range. What DHEA-S measures, why the literature treats it as a global endocrine marker, and what its decline means.
- BiomarkerTotal T 450 ng/dL
Total testosterone of 450 ng/dL in a 35-year-old man is technically inside the standard reference range but well below the age-matched mean. What the number means without free T and SHBG context — and what a deeper read tells you.
- BiomarkerSHBG low (male)
Sex hormone binding globulin below the male reference range is a strong signal of insulin resistance and metabolic syndrome — and it makes total testosterone readings deeply misleading. What the literature says.
- ResearchIpamorelin 10 mg
Ipamorelin is a selective ghrelin-receptor (GHSR) agonist. One of the cleanest pharmacological profiles in the growth-hormone-secretagogue class.
- ResearchCJC-1295 with DAC 5 mg
CJC-1295 with Drug Affinity Complex (DAC) — an extended GHRH analogue designed for half-life extension through covalent albumin binding.
- ResearchCJC-1295 no DAC 10 mg
CJC-1295 without DAC — short-acting modified GRF(1-29). Commonly used in preclinical GH-pulse research alongside ipamorelin.